BK virus

From IDWiki

Background

Microbiology

Epidemiology

  • Very high seroprevalence with asymptomatic infection ocurring in childhood
  • Disease is seen in immunosuppressed patients, especially renal transplant recipients
  • BKV nephropathy is seen in 1 to 10% of renal transplant recipients
  • BKV ureteric stenosis is seen in about 3% of renal transplant recipients
  • Hemorrhagic cystitis is seen in 10 to 25% of hematopoietic stem cell transplantation recipients

Clinical Manifestations

Nephropathy

  • Typically a cause of nephropathy in renal transplant patients
  • Onset is 10 to 13 months post-transplant, with a wide range of 6 days to 5 years
  • Presents with slowly increasing creatinine levels
    • Occasional hematuria and fever

Ureteral Stenosis

  • Causes urinary obstruction and AKI in the donor kidney, usually without pain since it is not innervated

Hemorrhagic Cystitis

Other Syndromes

Diagnosis

Nephropathy

  • Nephropathy: screening with urine or blood PCR followed by biopsy if concurrent renal dysfunction to confirm the diagnosis
  • BKV Transplantation Associated Virus Infections Working Group developed a consensus definition1
    • Proven: demonstration of active BKV within renal tissue by IHC for SV40 or ISH
    • Probable: requires all of the following:
      • Renal biopsy not performed or inadequate specimen
      • Renal transplant recipient receiving immunosuppression
      • Renal allograft dysfunction (≥20% rise in serum creatinine from baseline)
      • No likely alternative process
      • Significant BKPyV DNAemia in plasma on repeated measurement
        • For well-validated assays, >4 log10 copies/mL corresponds to biopsy-confirmed disease

Other

  • Hemorrhagic cystitis: urine PCR is relatively non-specific, although a high viral load may be supportive
  • Urine cytology may show decoy cells, though they are also seen in CMV and adenovirus

Management

  • There is no directed therapy
  • Nephropathy is typically managed by decreasing immunosuppression, monitoring viremia for response
  • Ureteral stenosis is similarly managed, but may require surgical intervention
  • Hemorrhagic cystitis is managed supportively, with continuous bladder irrigation, analgesia, hydration, and transfusion of platelets or erythrocytes as needed
    • Target for platelets is >50k

Prevention

  • In renal transplant patients, monitor for viremia monthly after transplant, decreasing immunosuppression if positive

References

  1. ^  Hannah Imlay, Paul Baum, Daniel C Brennan, Kimberly E Hanson, Michael R Hodges, Aimee C Hodowanec, Takashi E Komatsu, Per Ljungman, Veronica Miller, Yoichiro Natori, Volker Nickeleit, Jules O’Rear, Andreas Pikis, Parmjeet S Randhawa, Deirdre Sawinski, Harsharan K Singh, Gabriel Westman, Ajit P Limaye. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clinical Infectious Diseases. 2022;75(7):1210-1216. doi:10.1093/cid/ciac071.